Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma, US.
Oklahoma State University Medical Center, Tulsa, Oklahoma, US.
Methodist Debakey Cardiovasc J. 2021 Sep 22;17(3):13-17. doi: 10.14797/mdcvj.847. eCollection 2021.
We present the case of a healthy 29-year-old male with no significant medical history who presented with electrocardiogram findings consistent with pericarditis and elevated troponin levels, commonly seen in myocarditis, after receiving his second Pfizer-BioNTec vaccination for SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2). The patient had significant clinical improvement shortly after receiving aspirin and colchicine and was discharged home with these medications. His laboratory findings returned to baseline less than 2 weeks after his illness. While this case highlights the importance of diagnosis, intervention selection, and treatment of myopericarditis amid ongoing global vaccination campaigns, it should be emphasized that the benefits of vaccination considerably outweigh the risks.
我们报告了一例健康的 29 岁男性病例,他无明显病史,在接种第二剂辉瑞-生物技术公司的 SARS-CoV-2(严重急性呼吸综合征冠状病毒 2)疫苗后,出现符合心包炎的心电图表现和肌钙蛋白水平升高,这通常见于心肌炎。患者在接受阿司匹林和秋水仙碱治疗后很快获得了显著的临床改善,并在出院时带了这些药物。他的实验室检查结果在疾病发生后不到 2 周就恢复到基线水平。虽然本例强调了在持续的全球疫苗接种运动中对心肌心包炎进行诊断、干预选择和治疗的重要性,但应强调的是,疫苗接种的益处大大超过了风险。